List of Excipients in Branded Drug SFROWASA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	SFROWASA	mesalamine	0037-0022	CARBOMER HOMOPOLYMER TYPE B
Viatris Specialty LLC	SFROWASA	mesalamine	0037-0022	EDETATE DISODIUM
Viatris Specialty LLC	SFROWASA	mesalamine	0037-0022	POTASSIUM ACETATE
Viatris Specialty LLC	SFROWASA	mesalamine	0037-0022	SODIUM BENZOATE
Viatris Specialty LLC	SFROWASA	mesalamine	0037-0022	WATER

SFROWASA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

SFROWASA is a mesalamine 4 g/60 mL rectal suspension enema for ulcerative proctitis and other distal ulcerative colitis presentations. Its commercial value depends less on novel active-ingredient protection than on formulation performance, unit-dose packaging, patient retention, manufacturing consistency, and generic substitution economics. The key excipient platform uses carbomer 934P, xanthan gum, potassium acetate, sodium benzoate, and water for injection to create a stable, preservative-containing suspension that can be administered rectally and retained during treatment.[1]

What is SFROWASA and how does its formulation work?

SFROWASA contains mesalamine, also known as 5-aminosalicylic acid, at a dose of 4 g in 60 mL of rectal suspension. The product is locally delivered to the distal colon and rectum, limiting reliance on systemic exposure for therapeutic effect.[1]

Attribute	SFROWASA profile
Active ingredient	Mesalamine
Strength	4 g per 60 mL
Dosage form	Rectal suspension enema
Route	Rectal
Primary use	Ulcerative proctitis and distal ulcerative colitis
Regulatory application	NDA 019839
Product category	Small-molecule gastrointestinal anti-inflammatory
Biosimilar exposure	None
Primary substitution risk	Generic mesalamine enemas and alternative rectal formulations

The formulation is a suspension rather than a clear solution. This creates several technical requirements:

1. Mesalamine must remain adequately dispersed during storage and administration.
2. The vehicle must provide sufficient viscosity for mucosal contact and retention.
3. The product must remain physically stable across its labeled shelf life.
4. The preservative system must control microbial growth without compromising tolerability.
5. The container must deliver a consistent 60 mL dose.

Which excipients are used in SFROWASA?

The SFROWASA label identifies five inactive ingredients: carbomer 934P, potassium acetate, sodium benzoate, xanthan gum, and water for injection.[1]

Excipient	Likely formulation function	Commercial relevance
Carbomer 934P	Rheology modification, suspension support, viscosity control	Controls flow and retention properties
Xanthan gum	Suspending and thickening agent	Helps maintain uniform distribution of mesalamine
Potassium acetate	Buffering and ionic-strength control	Supports pH and physical stability
Sodium benzoate	Antimicrobial preservative	Supports multidose or liquid-product microbiological control
Water for injection	Aqueous vehicle	Determines solvent quality and manufacturing controls

The excipient strategy is functional rather than differentiated through a proprietary excipient. The commercial opportunity lies in reproducing or improving the performance envelope: viscosity, redispersibility, sedimentation rate, preservative effectiveness, dose uniformity, and patient acceptability.

How do carbomer and xanthan gum affect product performance?

Carbomer 934P and xanthan gum provide complementary rheology. Carbomer can increase viscosity and help suspend dispersed particles. Xanthan gum contributes pseudoplastic flow, allowing the formulation to become less viscous under shear during administration and more viscous at rest after delivery.

An abbreviated quality-by-design framework for a SFROWASA-like product would evaluate:

Critical quality attribute	Relevant excipient variable
Sedimentation rate	Polymer concentration and particle-size distribution
Redispersibility	Polymer network and mixing process
Administration force	Viscosity and nozzle geometry
Rectal retention	Yield stress and post-administration viscosity
Dose uniformity	Suspension homogeneity and container orientation
Microbial quality	Preservative concentration and packaging integrity
Chemical stability	pH, oxygen exposure, and raw-material impurities

The principal development risk is over-thickening. A formulation with excessive polymer content may improve suspension stability but increase administration resistance, residual volume, and patient dissatisfaction. A low-viscosity formulation may administer easily but settle rapidly and create dose nonuniformity.

What formulation patents protect SFROWASA?

The active ingredient, mesalamine, is an established small molecule with limited opportunity for broad composition-of-matter exclusivity. Product protection therefore depends on formulation, manufacturing, method-of-use, and regulatory exclusivity rights rather than on a new chemical entity patent.

Public FDA product information identifies SFROWASA as NDA 019839.[1] The FDA Orange Book is the controlling source for current patent listings and regulatory exclusivity associated with the application.[2] A current commercial assessment should distinguish among:

• patents listed in the Orange Book;
• expired formulation or method-of-use patents;
• unlisted manufacturing know-how;
• trade secrets covering suspension processing and filling;
• patents covering alternative mesalamine delivery systems.

The practical protection for SFROWASA is likely narrower than the brand name suggests. A generic sponsor can seek approval for a pharmaceutically equivalent mesalamine rectal suspension without copying every aspect of the branded manufacturing process, provided the proposed product satisfies FDA requirements for quality, performance, labeling, and therapeutic equivalence.

Does SFROWASA have active Orange Book protection?

The Orange Book, rather than the product label, determines whether active patents or exclusivity remain listed for NDA 019839. SFROWASA is an older mesalamine product, so its original regulatory and patent protections are unlikely to provide a durable barrier comparable to a recently approved product.[1,2]

The relevant diligence questions are:

Issue	Commercial implication
Listed drug patents	May trigger Paragraph IV certification and patent litigation
Expired patents	Do not block ANDA approval
Unlisted formulation know-how	Can raise manufacturing difficulty but does not independently delay FDA approval
Method-of-use claims	May support skinny-label or carve-out disputes
Regulatory exclusivity	Older products generally have limited remaining exclusivity

No biologic patent estate applies. Biosimilar litigation under the Biologics Price Competition and Innovation Act is irrelevant because SFROWASA is a small-molecule drug.

When does SFROWASA lose exclusivity?

SFROWASA is an older product and does not depend on current new-drug exclusivity for its commercial position. FDA approval of an ANDA, patent expiry, settlement terms, or a successful Paragraph IV challenge can enable generic entry.

Exclusivity category	Relevance to SFROWASA
New chemical entity exclusivity	Not applicable to this legacy mesalamine product
Five-year NCE exclusivity	Expired
Three-year clinical-investigation exclusivity	No current commercial significance
Orphan exclusivity	Not the principal protection for SFROWASA
Pediatric exclusivity	No current barrier identified from the product’s legacy status
Patent exclusivity	Must be checked against current Orange Book listings
Generic exclusivity	May attach to the first qualifying ANDA challenger

The commercial loss of exclusivity is therefore best analyzed through actual generic availability, not a single headline expiration date. A legacy product can remain commercially relevant after patent expiry when manufacturing complexity, low market size, and limited generic margins deter competitors.

Which companies are challenging SFROWASA?

Generic competition can arise through ANDA filings for mesalamine 4 g/60 mL rectal suspension or through therapeutically substitutable products such as mesalamine enemas, suppositories, and rectal foams.

A complete challenger analysis requires current FDA ANDA records, Orange Book data, court dockets, and commercial-launch information. The relevant legal mechanisms are:

• Paragraph IV certification against listed patents;
• Paragraph III certification where approval is deferred until patent expiry;
• section viii statements for method-of-use patents;
• 30-month stays following timely patent litigation;
• first-filer 180-day generic exclusivity where applicable.

For SFROWASA, the most important competitive threat may not be a patent challenger. It may be a generic manufacturer that obtains approval after demonstrating pharmaceutical equivalence and satisfies a market with relatively modest technical differentiation.

What generic entry risks exist for SFROWASA?

Generic entry risk is moderate to high from a legal perspective but may be constrained by technical and commercial factors.

Legal risk

Mesalamine is well characterized, and the product has an established route, strength, dosage form, and clinical use. These factors generally reduce the scientific uncertainty of an ANDA program. Any remaining listed patents would be the primary legal barrier.

Technical risk

Rectal suspensions require more development work than immediate-release oral tablets. A generic sponsor must control:

• particle-size distribution;
• suspension uniformity;
• sedimentation and redispersion;
• preservative effectiveness;
• container closure integrity;
• dose delivery;
• rheological behavior;
• microbial limits.

These requirements create a higher manufacturing burden than a simple tablet, but they do not necessarily support long-term exclusivity if the formulation principles are established.

Commercial risk

The market may not support many competitors because enemas are less convenient than oral or rectal alternatives. A generic entrant must account for:

• low-to-moderate prescription volume;
• product-specific manufacturing equipment;
• packaging and applicator costs;
• wholesaler and pharmacy inventory requirements;
• patient preference for foam or suppository products;
• substitution from oral mesalamine formulations.

A limited number of suppliers can preserve pricing better than expected after patent expiry. That effect is a market-structure issue, not a patent right.

What commercial opportunities exist in SFROWASA excipients?

The strongest opportunities are formulation improvements that address patient use and manufacturing efficiency.

Preservative-free formulations

Sodium benzoate is part of the labeled excipient system. A preservative-free presentation could target patients with sensitivity concerns or improve positioning in chronic-use populations. The development burden would shift toward aseptic processing, single-use packaging, or validated container closure systems.

The opportunity is commercially meaningful only if the new presentation demonstrates better tolerability, easier use, or reduced regulatory and manufacturing costs. Removing a preservative alone may not justify a premium.

Lower-volume rectal delivery

A 60 mL enema can create administration and retention challenges. A lower-volume product with higher mesalamine concentration could improve convenience, but it would require new work on suspension stability, local tolerability, dose uniformity, and delivery coverage.

Rectal foam or gel

Foams and gels may improve retention and administration compared with liquid enemas. The relevant intellectual-property opportunities include:

• propellant or propellant-free foam systems;
• bioadhesive polymers;
• metered-dose applicators;
• controlled spreading across rectal mucosa;
• reduced-volume delivery;
• unit-dose packaging.

These products would compete more on delivery experience than on mesalamine’s pharmacology.

Excipient supplier opportunities

Suppliers can create value through pharmaceutical-grade polymers, validated preservative systems, low-bioburden water systems, and technical support for suspension processing. The most defensible supplier position would combine excipient supply with formulation know-how, analytical methods, and regulatory documentation.

How strong is the SFROWASA patent estate?

The patent estate appears structurally weaker than that of a recently launched specialty product because:

1. mesalamine is an established active ingredient;
2. the dosage form is conventional;
3. the product has a long commercial history;
4. excipients are established pharmaceutical materials;
5. generic development does not require a new clinical efficacy program.

Its residual strength would depend on any active formulation or method-of-use claims, the breadth of those claims, and the ability to enforce them against an ANDA applicant. Manufacturing process knowledge may remain valuable even when it does not create an Orange Book barrier.

Protection layer	Relative strength
Active ingredient	Low
Core rectal dosage form	Low to moderate
Excipient combination	Moderate only if narrowly claimed and technically distinct
Manufacturing process	Potentially moderate as trade secret
Packaging and applicator	Moderate for differentiated systems
Method of use	Dependent on claim scope and label strategy
Regulatory exclusivity	Low for a legacy product

What patent litigation and settlement issues affect SFROWASA?

A Paragraph IV challenge could lead to patent litigation under the Hatch-Waxman framework. The key dates would be the ANDA notification date, patent-holder complaint date, 30-month stay, court judgment, settlement date, and authorized-generic launch.

Settlement agreements can affect generic entry through:

• agreed launch dates;
• licenses;
• authorized-generic commitments;
• supply arrangements;
• restrictions on formulation or manufacturing;
• acceleration clauses tied to patent outcomes.

No litigation conclusion should be inferred solely from the absence of a public product announcement. Patent disputes may be resolved through settlement or may never be publicly litigated if no listed patent creates a meaningful barrier.

How does SFROWASA compare with competing mesalamine products?

Product type	Main differentiation	Excipient opportunity	Competitive risk
SFROWASA-type enema	High local dose in 60 mL suspension	Rheology, preservative system, packaging	Generic suspension
Mesalamine suppository	Lower-volume rectal delivery	Suppository base and melting profile	Substitution in proctitis
Mesalamine foam	Improved retention and administration	Foam stabilizers and delivery device	Strong patient-preference competition
Oral delayed-release tablet	Broader colonic delivery	Enteric coating and release control	May reduce rectal-product demand
Oral extended-release capsule	Convenience and systemic distribution	Release-controlling polymers	Alternative for more extensive disease

SFROWASA is most defensible where localized rectal delivery is clinically preferred and the patient accepts enema administration. Its weakest position is convenience. Foam and suppository products can compete without duplicating the exact SFROWASA suspension.

What is the FDA regulatory status of SFROWASA?

SFROWASA is an FDA-approved mesalamine rectal suspension associated with NDA 019839.[1] The FDA label defines the active ingredient, strength, route, inactive ingredients, dosing instructions, warnings, and storage requirements.

For a new product based on the SFROWASA platform, the likely regulatory pathways are:

• ANDA for a pharmaceutically equivalent generic;
• 505(b)(2) application for a materially different formulation, delivery system, or route-related product;
• full NDA if the sponsor cannot rely sufficiently on existing findings and must establish a new benefit-risk profile.

A lower-volume foam, preservative-free system, or novel applicator may fit more naturally within a 505(b)(2) strategy than a conventional suspension that closely matches the reference product.

Key Takeaways

• SFROWASA is mesalamine 4 g/60 mL rectal suspension marketed for localized treatment of ulcerative proctitis and distal ulcerative colitis.
• Its labeled excipients are carbomer 934P, xanthan gum, potassium acetate, sodium benzoate, and water for injection.
• The formulation’s technical value lies in suspension stability, rheology, redispersibility, preservative control, and dose delivery.
• The product is a small-molecule drug, so biosimilar competition does not apply.
• Patent strength is likely concentrated in formulation, manufacturing, method-of-use, and device claims rather than active-ingredient protection.
• Generic entry risk is legally significant but may be moderated by manufacturing complexity and limited market size.
• The most attractive commercial opportunities are preservative-free systems, lower-volume delivery, rectal foam, bioadhesive gels, and improved applicators.
• Current Orange Book listings, ANDA filings, patent litigation, and settlement terms determine the operative exclusivity position.

FAQs about SFROWASA excipient and commercial strategy

Can carbomer 934P be replaced in a generic SFROWASA formulation?

Yes. A generic sponsor generally may use a different excipient system if the product meets FDA requirements for pharmaceutical equivalence, quality, stability, performance, and therapeutic equivalence.

Is sodium benzoate a patentable differentiator for SFROWASA?

Sodium benzoate alone is unlikely to create meaningful exclusivity. A patent position would require a novel, nonobvious formulation or performance relationship involving the preservative system.

Could a preservative-free SFROWASA product receive separate market protection?

Potentially. A preservative-free product with a materially different formulation or delivery system could support 505(b)(2) regulatory positioning and formulation or device patents, although the scope and duration of protection would depend on the claims and FDA exclusivity granted.

Is mesalamine foam a direct substitute for SFROWASA?

It can be a therapeutic and commercial alternative, but it is not necessarily pharmaceutically equivalent to a 4 g/60 mL rectal suspension. The products differ in dosage form, excipient system, administration characteristics, and regulatory pathway.

What is the main manufacturing barrier for a generic SFROWASA product?

The principal barrier is consistent control of suspension uniformity, sedimentation, redispersion, preservative effectiveness, container delivery, and product performance through shelf life.

References

1. DailyMed. (n.d.). SFRowasa: Mesalamine 4 g/60 mL rectal suspension prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2019). Product-specific guidance for mesalamine rectal suspension. FDA.
4. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin: Guidance for industry. FDA.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.